Kringle Pharma, Inc. (TYO:4884)
510.00
-64.00 (-11.15%)
Nov 18, 2026, 11:10 AM JST
Kringle Pharma Balance Sheet
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Cash & Equivalents | 1,681 | 1,619 | 2,313 | 2,136 | 2,756 |
Cash & Short-Term Investments | 1,681 | 1,619 | 2,313 | 2,136 | 2,756 |
Cash Growth | 3.83% | -30.00% | 8.29% | -22.50% | 28.97% |
Accounts Receivable | - | - | - | 7 | - |
Other Receivables | 51 | 60 | 57 | 74 | 67 |
Receivables | 51 | 60 | 57 | 81 | 67 |
Inventory | 179 | 250 | 294 | 364 | 349 |
Prepaid Expenses | 20 | 20 | 23 | 14 | 11 |
Other Current Assets | 7 | 106 | 68 | 22 | 24 |
Total Current Assets | 1,938 | 2,055 | 2,755 | 2,617 | 3,207 |
Long-Term Investments | 38 | 23 | 1 | 1 | 1 |
Other Long-Term Assets | 1 | 1 | 1 | - | - |
Total Assets | 1,977 | 2,079 | 2,757 | 2,618 | 3,208 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Accounts Payable | 1 | 1 | 1 | - | 1 |
Accrued Expenses | 12 | 15 | 21 | 5 | 2 |
Current Income Taxes Payable | 91 | 21 | 37 | 173 | 54 |
Other Current Liabilities | 76 | 72 | 69 | 31 | 105 |
Total Current Liabilities | 180 | 109 | 128 | 209 | 162 |
Other Long-Term Liabilities | 631 | 662 | 522 | 388 | 258 |
Total Liabilities | 811 | 771 | 650 | 597 | 420 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Common Stock | 64 | 64 | 11 | 97 | 59 |
Additional Paid-In Capital | 1,878 | 2,888 | 2,835 | 3,095 | 3,057 |
Retained Earnings | -813 | -1,672 | -756 | -1,185 | -331 |
Comprehensive Income & Other | 37 | 28 | 17 | 14 | 3 |
Shareholders' Equity | 1,166 | 1,308 | 2,107 | 2,021 | 2,788 |
Total Liabilities & Equity | 1,977 | 2,079 | 2,757 | 2,618 | 3,208 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Net Cash (Debt) | 1,681 | 1,619 | 2,313 | 2,136 | 2,756 |
Net Cash Growth | 3.83% | -30.00% | 8.29% | -22.50% | 28.97% |
Net Cash Per Share | 217.58 | 236.63 | 361.45 | 396.27 | 567.55 |
Filing Date Shares Outstanding | 8.46 | 7.02 | 6.81 | 5.41 | 5.38 |
Total Common Shares Outstanding | 8.46 | 7.02 | 6.81 | 5.41 | 5.38 |
Working Capital | 1,758 | 1,946 | 2,627 | 2,408 | 3,045 |
Book Value Per Share | 137.80 | 186.38 | 309.37 | 373.88 | 518.16 |
Tangible Book Value | 1,166 | 1,308 | 2,107 | 2,021 | 2,788 |
Tangible Book Value Per Share | 137.80 | 186.38 | 309.37 | 373.88 | 518.16 |